Trial Profile
An Open-label, Parallel-group, Single Centre, Single Oral Dose Study to Investigate the Pharmacokinetics of 50 mg Safinamide in Subjects With Mild and Moderate Hepatic Impairment as Compared to Matched Subjects With Normal Hepatic Function.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Mar 2018
Price :
$35
*
At a glance
- Drugs Safinamide (Primary)
- Indications Alzheimer's disease; Epilepsy; Parkinson's disease; Restless legs syndrome
- Focus Pharmacokinetics
- Sponsors Newron Pharmaceuticals
- 24 Dec 2009 New trial record